Evidence brief
Tesamorelin
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Direct answer
An FDA-approved product exists for a narrow indication.
An approved medicine for one specific HIV-related body-composition outcome. It is not a general weight-loss or anti-aging medicine.
- How strong is the evidence?
- Established
An official agency review or strong, repeated studies in people support one clear use. That evidence applies only to the product, people, and use we reviewed. It does not mean the product is safe or effective for everyone. - What evidence exists?
- Approved human outcomes
Approved products have evidence from studies in people that measured health results for specific uses. This does not show that every product, person, or use has the same result. - Sports rules
- Prohibited
The checked rules list this substance or group as prohibited under the stated conditions. Check the current rules for your sport.
Reviewed August 1, 2026. Sources and update notes are below.
No sales or dosing advice. This guide explains research. It was not independently medically reviewed, and it does not diagnose, prescribe, or recommend treatment.
Also known as Egrifta SV · Egrifta WR · TH9507 · GHRF analogue
Part of Growth hormone peptides
Words used here
- indication
- the approved or studied use and patient group
- outcome
- what the study measured
- analog
- a changed version made to act like another substance
- formulation
- the ingredients and physical form of the finished product
- compounded
- made for one patient by a pharmacy, or in batches by a permitted outsourcing facility; a compounded drug is not FDA-approved
- randomized
- assigned to study groups by chance
- peptide
- a short chain of amino acids
- amino acid
- a small building block that makes peptides and proteins
More detailProduct and study details
01 · Evidence profile
Four questions about the evidence
Phase 3 trials support visceral-adipose-tissue reduction in the labeled HIV population.
The approved label characterizes IGF-1 response, exposure, and product-specific use.
The label describes neoplasm, glucose, fluid-retention, hypersensitivity, and other risks.
High for authentic Egrifta SV; no automatic transfer to other formulations.
02 · Identity
What it is
Tesamorelin is a changed version of a body signal that releases growth hormone. The approved product has a narrow labeled group of people and outcome.
Scientific group: Growth hormone-releasing factor analogue. This group name describes the type of molecule or body signal. It does not prove a benefit, safety, or approval.
03 · Exact product
The molecule is not the finished product.
Formulation: The finished product's ingredients and physical form. Route: How the product enters the body. Indication: The approved or studied use and group of people for a product.
Egrifta SV
2024 label- Formulation
- 2 mg single-dose vial
- Route
- Subcutaneous
- Indication scope
- Reduction of excess abdominal fat in adults with HIV and lipodystrophy; not indicated for weight-loss management.
Egrifta WR
March 2025- Formulation
- 11.6 mg single-patient-use multidose vial
- Route
- Subcutaneous
- Indication scope
- Reduction of excess abdominal fat in adults with HIV and lipodystrophy; not indicated for weight-loss management.
- Egrifta SV
- Egrifta WR
- Reduction of excess abdominal fat in adults with HIV and lipodystrophy
04 · Research results
What the research shows
Controlled trials in adults with HIV-associated abdominal fat accumulation found less visceral fat, which is fat around internal organs. The Egrifta SV and Egrifta WR labels say the products are not indicated for weight-loss management and that long-term cardiovascular safety has not been established. Their formulations are not substitutable.
These results do not establish general fat loss, muscle gain, anti-aging benefit, athletic recovery, or equivalent outcomes from compounded products.
Exact product
The two approved products are not interchangeable. Egrifta SV and Egrifta WR are approved, non-substitutable formulations with product-specific labeling. Tesamorelin sold or compounded outside those products is not automatically equivalent.
05 · Claim check
Claims I checked
3 claims checked for this brief.
“Tesamorelin reduces visceral fat in adults with HIV-associated lipodystrophy.”
Phase 3 trials and the product label support this outcome in the labeled population.
- Evidence used
- Randomized human outcomes. This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- Adults with HIV and excess abdominal fat meeting the trial and label criteria. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Tesamorelin is an approved general weight-loss drug.”
The label specifically says it is not indicated for weight-loss management.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- The current Egrifta SV and Egrifta WR labels. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
“Tesamorelin is permitted for competitive athletes.”
The 2026 WADA Prohibited List names tesamorelin in the S2 peptide-hormone and growth-factor category, which is prohibited at all times for covered athletes.
- Evidence used
- Regulatory or product record. This answer uses an official regulator record or a specific product label.
- Limits of this answer
- Sport governed by the World Anti-Doping Code. This answer covers only the named molecule and finished product. It also covers the product form and how people used it. The study limits include who took part, what was used for comparison, what changed, and how long the study lasted.
06 · Questions
Questions people ask about Tesamorelin
An FDA-approved product exists for a narrow indication. Approved products identified: Egrifta SV, Egrifta WR.
Prohibited. Tesamorelin is named as a prohibited growth-hormone-releasing hormone analogue on the 2026 WADA Prohibited List and is prohibited at all times for covered athletes. This status is not personal clearance to compete.
Controlled trials in adults with HIV-associated abdominal fat accumulation found less visceral fat, which is fat around internal organs. The Egrifta SV and Egrifta WR labels say the products are not indicated for weight-loss management and that long-term cardiovascular safety has not been established. Their formulations are not substitutable.
These results do not establish general fat loss, muscle gain, anti-aging benefit, athletic recovery, or equivalent outcomes from compounded products.
07 · Safety
Safety limits for this record
This prescription drug has benefits for a specific group and important monitoring requirements. No dosing, cycling, stacking, or performance-use guidance is provided.
Tesamorelin is named as a prohibited growth-hormone-releasing hormone analogue on the 2026 WADA Prohibited List and is prohibited at all times for covered athletes.
The checked rules list this substance or group as prohibited under the stated conditions. Check the current rules for your sport.
Reviewed .Check current rules for tested sport ↗Open the governing record ↗08 · Sources
Read the sources
09 · Review history
Review history
Revalidated the current Egrifta WR indication and weight-loss limitation against FDA labeling, and confirmed tesamorelin remains named on the 2026 WADA Prohibited List.
Updated for Egrifta SV and Egrifta WR product identity, non-substitutability, phase 3 outcomes, and the 2026 WADA list.
Written and source-checked by Anthony Treviso, founder of The Peptide Field.
Not independently medically reviewed. This page is not a dosing, sourcing, or treatment guide.